Former Apogee executives are joining biotech builder Paragon after Apogee’s $10.9 billion exit to AbbVie.

The leaders are expected to help scale Paragon’s research and development engine.

They will also strengthen Paragon’s company creation capabilities, the article reports.

Paragon has focused on expanding its operational capacity and internal infrastructure.

Analysts say such executive moves often come before news on clinical trials and funding rounds.

Another Paragon spinout recently went public through a reverse merger, a headline cited in the article says.

Experts say big liquidity events often trigger a wave of talent moving between top firms.

More updates on the executive appointments are expected in the coming quarter.

Read the full article for more details on the Apogee leadership move to Paragon.